Aleglitazar
From Infogalactic: the planetary knowledge core
Names | |
---|---|
IUPAC name
(2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-7-benzothiophenyl]propanoic acid
|
|
Other names
Ro-0728804, R-1439
|
|
Identifiers | |
475479-34-6 | |
ChEMBL | ChEMBL519504 |
ChemSpider | 8450255 |
DrugBank | DB08483 |
7405 | |
Jmol 3D model | Interactive image Interactive image |
KEGG | D08845 |
PubChem | 10274777 |
UNII | 41T4OAG59U |
|
|
|
|
Properties | |
C24H23NO5S | |
Molar mass | 437.51 g·mol−1 |
Vapor pressure | {{{value}}} |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
verify (what is ?) | |
Infobox references | |
Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes.[1] It is no longer in phase III clinical trials.[2]
References
<templatestyles src="Asbox/styles.css"></templatestyles>